| Variables | Number of OI | Mean survival time in days [95 %CI] | P | |
|---|---|---|---|---|
| Age group (yrs) | < 30 30-39 40-49 ≥50 |
46 21 12 4 |
620.93[585.173,656.685] 632.70[587.857,677.550] 652.22[599.260,705.175] 601.58[491.012,712.155] |
0.757 |
| Sex |
Female Male |
45 38 |
634.09[603.441,664.735] 621.39[582.296,660.479] |
0.329 |
| BMI |
< 18.5 ≥ 18.5 |
55 28 |
594.27[555.615,632.922] 661.52[632.772,690.278] |
0.001 |
| Marital status |
Single Married Widowed Separated |
10 36 5 9 |
631.97[562.164,701.775] 592.67[546.266,639.070] 643.37[574.149,712.584] 612.30[580.625,643.97] |
0.615 |
| Educational level |
Not Educated Primary Secondary Tertiary |
24 25 21 12 |
566.89[503.064,630.719] 651.11[614.903,687.324] 655.27[615.672,694.875] 610.26[535.895,684.626] |
0.089 |
| CD4 count |
< 100 100-199 200-350 > 350 |
25 37 19 2 |
629.11[583.779,674.431] 617.88[578.817,656.949] 651.09[609.222,692.964] 511.40[263.608,759.192] |
0.521 |
| Risky behaviors |
Yes No |
25 58 |
647.35[608.379,686.314] 618.54[587.838,649.236] |
0.241 |
| Baseline comorbidity | Yes No |
3 80 |
675.28[587.677,762.878] 626.02[600.930,651.113] |
0.313 |
| Baseline OI |
Yes No |
62 21 |
624.29[595.897,652.684[ 642.80[597.438,688.167] |
0.818 |
| Cotrimoxazole prophylaxis | Yes No |
81 2 |
629.56[605.258,653.856] 609.00[458.693,759.307] |
0.676 |
| Fluconazole Prophylaxis | Yes No |
5 78 |
544.00[410.554,677.446] 632.73[608.431,657.035] |
0.389 |
| INH prophylaxis | Yes No |
42 41 |
577.50[512.176,642.833] 640.46[615.170,665.833] |
0.083 |
| Baseline HAART | D4T based AZT based TDF based |
60 18 5 |
614.44[583.314,645.574] 617.08[558.409,675.759] 628.86[604.828,652.887] |
0.051 |
| Baseline WHO | Stage I Stage II Stage III Stage IV |
15 15 44 9 |
649.68[598.913,700.445] 666.86[628.711,705.013] 598.24[556.866,639.611] 609.18[530.651,687.706] |
0.066 |